Institutional Regenerative Medicine
Why trust OmniStem?
Licensure, laboratory infrastructure, and quality protocols that distinguish institutional regenerative medicine from the broader market.
Regenerative medicine has a global trust deficit. The points below describe the licensure, infrastructure, and documentation that govern OmniStem's clinical and laboratory operations — the framework that distinguishes institutional regenerative medicine from the unregulated end of the field.
i
Licensed clinical & laboratory infrastructure
OmniStem operates under Dominican Republic Ministry of Health authorization with both clinical treatment licensure and laboratory and stem cell banking authorization.
ii
GMP-aligned laboratory operations
Biologics are processed within OmniStem's own GMP-aligned laboratory under controlled handling procedures and traceable batch documentation.
iii
Triple-layer quality testing
Every released biologic batch undergoes:
- Sterility testing
- Viability assessment
- Identity characterization
iv
Certificate of Analysis
Patients receive batch-specific documentation including:
- Preparation date
- Cell count & viability percentage
- Sterility confirmation & release verification
- Name of the scientist who certified the batch
v
Wharton's Jelly-derived UC-MSC platform
OmniStem utilizes Wharton's Jelly-derived UC-MSCs selected for their low immunogenic profile and signaling properties — a tissue source associated with younger, more proliferative cells than adult-derived MSCs.
vi
Punta Cana accessibility
Located minutes from Punta Cana International Airport, with direct access from major North American hubs. Concierge logistics — reception, transportation, and accommodation coordinated end to end.